Needham analyst Michael Matson has maintained their neutral stance on ZBH stock, giving a Hold rating on April 24.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Michael Matson has given his Hold rating due to a combination of factors, including a quarter in which Zimmer Biomet modestly exceeded revenue expectations and delivered an earnings beat that was helped by tariff-related refunds. Management kept its 2026 sales outlook intact while only nudging up the lower bound of earnings guidance, which signals limited incremental upside from current forecasts.
At the same time, the company’s underlying organic revenue growth decelerated, and Matson’s analysis suggests Zimmer Biomet slightly ceded reconstruction market share in a slowing global market. The unexpected departure of the CFO and the appointment of an interim finance head add a layer of uncertainty, and with only low-single-digit top-line expansion and challenges in driving substantial EPS growth, he sees the risk/reward as balanced rather than compelling for new buyers.
In another report released on April 24, Canaccord Genuity also maintained a Hold rating on the stock with a $93.00 price target.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZBH in relation to earlier this year.